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Background: Sutureless aortic valve replacement (SU-AVR) has been developed as an alternative surgical 
treatment for patients with symptomatic severe aortic stenosis (AS). The aim of this study was to evaluate 
the clinical outcomes of SU-AVR through an assessment of hemodynamic performance and safety. Methods: 
From December 2014 to June 2016, a total of 12 consecutive patients with severe AS underwent SU-AVR. 
The endpoints were overall survival and valve-related complications (paravalvular leakage, valve thrombosis, 
migration, endocarditis, and permanent pacemaker implantation). The mean follow-up duration was 18.1±8.6 
months. Results: The mean age of the patients was 77.1±5.8 years and their mean Society of Thoracic 
Surgeons score was 9.2±17.7. The mean cardiopulmonary bypass and aortic cross-clamp times were 
94.5±37.3 minutes and 54.9±12.5 minutes, respectively. Follow-up echocardiography showed good prosthesis 
function with low transvalvular pressure gradients (mean, 13.9±8.6 mm Hg and peak, 27.2±15.0 mm Hg) at 
a mean of 9.9±4.2 months. No cases of primary paravalvular leakage, valve thrombosis, migration, or endo-
carditis were reported. A new permanent pacemaker was implanted in 1 patient (8.3%). The 1-year overall 
survival rate was 83.3%±10.8%. Conclusion: Our initial experience with SU-AVR demonstrated excellent early 
clinical outcomes with good hemodynamic results. However, there was a high incidence of permanent pace-
maker implantation compared to the rate for conventional AVR, which is a problem that should be solved.
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Introduction
Conventional aortic valve replacement (AVR) for 
patients with symptomatic severe aortic stenosis (AS) 
is recommended as the gold-standard treatment to 
alleviate symptoms and to improve survival [1-5]. 
The outcomes of AVR have improved over the past 
decades, but the incidence of mortality and morbidity 
after surgical management remain high among pa-
tients with older age and multiple comorbidities 
[6-8]. In recent years, as the number of high-risk eld-
erly patients has increased, technological advances 
have led to less invasive alternative treatment modal-
ities, including sutureless AVR (SU-AVR) and trans-
catheter aortic valve implantation (TAVI), which have 
expanded the indications for surgery to include high- 
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or prohibitive-risk patients [4]. SU-AVR, which in-
volves a rapidly deploying aortic valve device, has 
the advantages of reducing the cardiopulmonary by-
pass (CPB) duration and aortic cross-clamp (ACC) 
time, thereby minimizing the operative risk, and en-
abling the straightforward implantation of an aortic 
biologic valve prosthesis without sutures through a 
minimally invasive approach [4,9,10]. Several studies 
have reported that these sutureless valves resulted in 
a lower incidence of postoperative complications, es-
pecially misplacement and paravalvular leakage, be-
cause they involve the direct removal of the calcified 
valve and allow accurate debridement of the diseased 
aortic annulus [9,11,12]. The aim of this study was 
to evaluate retrospectively the 1-year clinical and 
echocardiographic outcomes of SU-AVR through an 
assessment of hemodynamic performance and safety.
Methods
Between December 2014 and June 2016, a total of 
12 consecutive patients with severe AS who under-
went SU-AVR at Severance Cardiovascular Hospital, 
Yonsei University College of Medicine were reviewed. 
All patients were implanted with the Perceval valve 
system (Sorin Group Srl, Saluggia, Italy), which is a 
self-expanding, self-anchoring, sutureless bioprosthetic 
valve [13]. Patients with a congenital bicuspid aortic 
valve, an asymmetric aortic annulus, an annulus-to-si-
notubular-junction ratio greater than 1.3, and an 
aortic annulus diameter less than 19 mm or greater 
than 27 mm were excluded from this study [12-14]. 
Transthoracic echocardiography (TTE) and coro-
nary-valve computed tomography were routinely per-
formed preoperatively to assess valvular morphology.
Preoperative and perioperative data were obtained 
from a review of the patients’ hospital charts, and 
follow-up was performed when patients returned for 
follow-up visits or by conducting telephone interviews. 
The collection of follow-up data for at least 1 year 
was complete (100%). All patients underwent a clin-
ical evaluation, blood tests, and TTE at each fol-
low-up visit. The preoperative variables included in 
the analysis were age, sex, body surface area, hyper-
tension, diabetes mellitus, coronary artery disease, 
chronic obstructive pulmonary disease, chronic kid-
ney disease, arrhythmia, a history of a previous per-
cutaneous coronary intervention or cardiac operation, 
New York Heart Association (NYHA) functional class, 
Society of Thoracic Surgeons (STS) score, the logistic 
European System for Cardiac Operative Risk Evalua-
tion (Euroscore), and echocardiographic indicators 
(left ventricular ejection fraction, aortic valve area, 
peak and mean systolic pressure gradient, left atrial 
diameter, left ventricular end systolic and diastolic 
dimension, left atrial volume index, left ventricular 
mass index, and right ventricular systolic pressure). 
High-risk patients were defined as those with an STS 
operative risk score of 8% or higher.
The following perioperative variables were re-
corded: CPB and ACC time, valve size, and any con-
comitant cardiac procedures. Clinical outcomes were 
assessed in terms of all-cause mortality and post-
operative valve-related complications. Valve-related 
events were defined as valve thrombosis, embolism, 
and bleeding events (formerly anticoagulant hemor-
rhage) according to the American Association for 
Thoracic Surgery guidelines for reporting morbidity 
and mortality after cardiac valve interventions [15].
1) Operative techniques
All operations were performed under CPB using 
systemic hypothermia through a median or minimal 
invasive upper sternotomy. A transverse aortotomy 
in a relatively high position, approximately 3.5 cm 
above the aortic annulus, was performed to accom-
modate the height of the prosthetic stent. After de-
calcification of the aortic annulus, the expandable 
stent was implanted in the appropriate annular posi-
tion without any permanent suture. We routinely 
used specific sizers for the optimal valve size and 3 
guiding sutures between 2 commissures to correctly 
insert the valve at the level of the native aortic 
annulus. The prosthesis was then released into the 
valve and dilated with a low-pressure balloon cathe-
ter for 30 seconds at a pressure of 4 atmospheres 
[12,13,16]. When the valve was successfully de-
ployed, the guiding sutures were removed.
2) Statistical analysis
Statistical analyses were performed using IBM 
SPSS ver. 23.0 (IBM Corp., Armonk, NY, USA). All da-
ta are presented as mean±standard deviation or as 
frequency and percentage. Continuous variables were 
analyzed using the Student t-test, and categorical var-
iables were compared using the chi-square test or 
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Table 1. Baseline patients’ characteristics (N=12)
Variable Value
Age (yr) 77.1±5.8 (62.0–85.0)
≥80 years older 4 (33.3)
Sex (female) 7 (58.3)
Body surface area (m
2
) 1.68±0.17 (1.44–1.98)
Hypertension 10 (83.3)
Diabetes mellitus 5 (41.7)
Coronary artery disease 3 (25.0)
Chronic obstructive pulmonary disease 3 (25.0)
Chronic kidney disease 1 (8.3)
Peripheral artery disease 0
Cardiac rhythm
Sinus rhythm 8 (66.7)
Atrial fibrillation 2 (16.7)
Pacemaker 2 (16.7)
Previous cardiac operation 3 (25.0)
NYHA class III 11 (91.7)
NYHA class IV 1 (8.3)
Society of Thoracic Surgeons score 9.2±17.7 (0.9–64.3)
Logistic Euroscore 16.2±19.2 (3.3–75.0)
Euroscore II 7.8±11.8 (1.9–42.4)
Values are presented as mean±standard deviation (range) or 
number (%).
NYHA, New York Heart Association; Euroscore, European System 
for Cardiac Operative Risk Evaluation.
Table 2. Preoperative echocardiographic data (N=12)
Variable Value
Aortic valve lesion
Stenosis 12 (100.0)
Moderate 1 (8.3)
Severe 11 (91.7)
Stenosis and regurgitation 
(grade ≥II)
3 (25.0)
Left ventricular ejection fraction (%) 61.4±13.9 (28–75)
E/E’
a)
22.6±7.0 (10–30)
Aortic valve area (cm
2
) 0.75±0.15 (0.44–0.96)
Peak systolic pressure gradient 
(mm Hg)
79.8±17.8 (48–112)
Mean systolic pressure gradient 
(mm Hg)
47.7±9.3 (32–62)
Left atrial diameter (mm) 51.3±16.7 (37–96)
Left ventricular end systolic 
dimension (mm)
33.9±5.8 (26–44)
Left ventricular end diastolic 
dimension (mm)
50.4±4.9 (44–62)
Left atrial volume index (mL/m
2
) 48.7±8.3 (38.4–67.7)
Left ventricular mass index (g/m
2
) 137.3±30.0 (72.1–173.2)
Right ventricular systolic pressure 
(mm Hg)
38.4±14.6 (23–75)
Aortic valve annulus (mm) 23.3±1.1 (21.5–25.3)
Sinotubular junction (mm) 26.1±3.2 (21.2–31.3)
Annulus/sinotubular junction ratio 0.9±0.1 (0.8–1.1)
Height (mm) 19.2±3.4 (15.4–27.8)
Values are presented as number (%) or mean±standard deviation 
(range).
a)
Ratio of early diastolic transmitral velocity to early diastolic tis-
sue velocity.
the Fisher exact test. The long-term survival curve 
was evaluated using the Kaplan-Meier method. All 
p-values less than 0.05 were considered to indicate 
statistical significance, and rates are expressed with 
95% confidence limits.
Results
1) Patient characteristics and preoperative echo-
cardiographic data
The mean age of the patients was 77.1±5.8 years 
(range, 62.0 to 85.0 years) and 33.3% were at least 
80 years old. The study population consisted of 7 
women (58.3%) and 5 men (41.7%). The pre-
operative characteristics of the patients and their 
cardiovascular comorbidities are summarized in 
Table 1. Eleven patients (91.7%) were classified as 
NYHA functional class III, and 1 (8.3%) was classified 
as NYHA functional class IV. The mean STS score 
was 9.2±17.7, the logistic Euroscore was 16.2±19.2, 
and the Euroscore II was 7.8±11.8. In 3 patients 
(25.0%), previous cardiac surgery was performed be-
fore the SU-AVR procedure, such as coronary artery 
bypass grafting or mitral valve replacement. As 
shown in Table 2, the preoperative left ventricular 
ejection fraction was 61.4%±13.9% (range, 28% to 
75%) and the peak and mean systolic pressure gra-
dients were 79.8±17.8 mm Hg and 47.7±9.3 mm Hg, 
respectively.
2) Perioperative data
The sutureless valve was successfully implanted in 
all patients (Fig. 1). One patient required a second 
attempt due to size mismatching. The valves were 
sized medium (n=5, 41.7%), large (n=4, 33.3%), and 
extra-large (n=3, 25.0%). Eleven patients underwent 
isolated AVR, and concomitant coronary artery by-
pass grafting was performed in 1 patient with 3-ves-
sel disease. Minimally invasive surgery (upper ster-
Do Jung Kim, et al
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Table 3. Perioperative data
Variable Value
Surgical approach
Median sternotomy 6 (50.0)
Minimal invasive approach 6 (50.0)
Valve size
S (21 mm) 0
M (23 mm) 5 (41.7)
L (25 mm) 4 (33.3)
XL (27 mm) 3 (25.0)
Cardiopulmonary bypass time (min) 94.5±37.3 (55.0–183.0)
Aortic cross clamp time (min) 54.9±12.5 (39.0–87.0)
Concomitant cardiac surgery
Coronary artery bypass grafting 1 (8.3)
Values are presented as number (%) or mean±standard deviation 
(range).
Table 4. Clinical outcomes
Variable Value
Reoperation for bleeding 0
Newly required dialysis 0
Delayed ventilation 1 (8.3)
Early stroke 0
Gastrointestinal bleeding 0
Arrhythmia/pacemaker implantation 2 (16.7)/1 (8.3)
Hospital stay (day) 16.8±14.8 (7–59)
Postoperative New York Heart Association class
I 5 (41.7)
II 7 (58.3)
In hospital mortality 0
Late mortality 3 (25.0)
Valve thrombosis 0
Endocarditis 0
Valve migration 0
Paravalvular leak 0
Values are presented as number (%) or mean±standard deviation 
(range).
Fig. 1. Computed tomography scan performed 1 month post-
operatively, showing a well-functioning Perceval S sutureless 
bioprosthesis. A, anterior; P, posterior; H, head; F, foot.
Fig. 2. Kaplan-Meier curve showing the overall survival rate in 
patients who were implanted with a sutureless valve (SU-AVR). 
SU-AVR, sutureless aortic valve replacement.
notomy) was performed in 6 patients (50.0%). Three 
patients underwent redo surgery. The mean CPB and 
ACC times were 94.5±37.3 minutes and 54.9±12.5 
minutes, respectively (Table 3).
3) Clinical outcomes
The mean follow-up duration was 18.1±8.6 months 
(range, 3.3 to 28.9 months). The overall survival rate 
at 1 year was 83.3%±10.8%. The Kaplan-Meier risk 
curve for overall survival is shown in Fig. 2. There 
was no case of 30-day in-hospital mortality. Three 
patients (25.0%) in the population died during the 
follow-up period. The causes of death were cerebral 
hemorrhage (n=1), fungal sepsis (n=1), and gastro-
intestinal bleeding due to the rupture of esophageal 
varices (n=1). An 81-year-old woman who had 
worked at a sanatorium as a physician died at 3.3 
months postoperatively due to septic shock with cul-
tured Candida albicans, and another 81-year-old 
woman with an uncontrolled international normal-
ized ratio died during follow-up due to anti-
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Table 5. Hemodynamic data from postoperative to latest follow-up
Variable Pre Post
p-value (pre 
vs. post)
Latest
p-value (pre 
vs. latest)
Δ Mean 
(pre-last)
Left ventricular ejection fraction (%) 61.4±13.9 56.9±5.8 0.168 57.6±11.8 0.058 −3.8±6.3
E/E’
a)
22.6±7.4 26.0±8.6 0.248 26.6±9.1 0.189 5.4±10.4
Aortic valve area (cm
2
) 0.77±0.15
Peak systolic pressure gradient (mm Hg) 79.8±17.8 30.2±9.0 ＜0.001 27.2±15.0 ＜0.001 −52.6±24.4
Mean systolic pressure gradient (mm Hg) 47.7±9.3 16.7±5.1 ＜0.001 13.9±8.6 ＜0.001 −33.8±12.8
Left atrial diameter (mm) 51.3±16.7 45.9±7.2 0.139 47.2±6.7 0.300 −4.2±13.3
Left ventricular end systolic dimension (mm) 33.9±5.8 34.9±4.4 0.491 34.0±5.8 0.948 0.1±4.3
Left ventricular end diastolic dimension (mm) 50.4±4.9 47.3±4.9 0.040 47.8±5.7 0.145 −2.6±5.7
Left atrial volume index (mL/m
2
) 48.7±8.3 47.8±12.5 0.651 51.0±22.6 0.628 2.3±16.1
Left ventricular mass index (g/m
2
) 137.3±30.0 120.7±29.4 0.057 104.2±39.8 0.006 −33.2±34.2
Right ventricular systolic pressure (mm Hg) 38.4±14.6 40.9±14.1 0.520 37.1±13.0 0.677 −1.3±9.8
Values are presented as mean±standard deviation.
Pre, preoperative; Post, postoperative.
a)
Ratio of early diastolic transmitral velocity to early diastolic tissue velocity.
coagulation-related hemorrhage.
No cases of postoperative paravalvular leakage, 
valve thrombosis, migration, or endocarditis were re-
ported (Table 4). Arrhythmia occurred in 2 cases 
(16.7%). A new permanent pacemaker was implanted 
in 1 patient as a result of postoperative third-degree 
atrioventricular block. No patients underwent reoper-
ation due to bioprosthesis valve dysfunction. The 
NYHA functional class improved by at least 1 level in 
all patients (class I, 41.7% and class II, 58.3% at the 
1-year follow-up).
The echocardiographic outcomes of the survivors 
at 6–12 months postoperatively are summarized in 
Table 5. The mean echocardiographic follow-up dura-
tion was 9.9±4.2 months (range, 2.5 to 14.2 months). 
All valves functioned well. The final peak systolic 
pressure gradient was 27.2±15.0 mm Hg, and the 
mean gradient was 13.9±8.6 mm Hg. In terms of he-
modynamic outcomes, the changes in the peak sys-
tolic pressure gradient, mean systolic pressure gra-
dient, and the left ventricular mass index showed sig-
nificant improvement: −52.6±24.4 mm Hg (p＜0.001), 
−33.8±12.8 mm Hg (p＜0.001), and −33.2±34.2 g/m
2
 
(p=0.006), respectively.
Discussion
This study evaluated early clinical outcomes in pa-
tients who underwent SU-AVR for symptomatic se-
vere AS. In this initial experience, there were no 
prosthesis-related complications such as paravalvular 
leakage, valve thrombosis, reoperation, or endocarditis. 
All patients showed an improved NYHA functional 
class to grade II or less (grade I, 41.7% and grade II, 
58.3%).
Recently, TAVI and SU-AVR were developed to 
minimize the adverse effects in previously inoperable 
high-risk patients [3,10-12,17]. At our institution, we 
have used sutureless valves as an alternative treat-
ment option to reduce the surgical risk and to facili-
tate minimally invasive procedures in aged and 
high-risk patients with comorbidities. Indications for 
SU-AVR in our early series were patients with sig-
nificant comorbidities who were at least 75 years of 
age, or patients with a significant surgical risk in 
whom concomitant procedures requiring a long CPB 
time were planned.
Previous studies have reported that an increased 
risk for mortality was associated with the duration of 
CPB and ACC, and that these factors were in-
dependent predictors of survival [3-5]. A potential 
advantage of SU-AVR in comparison to conventional 
AVR is the reduced CPB and ACC time, due to the 
rapid sutureless deployment [9,10,17]. In the European 
multicenter Cavalier trial, the mean ACC and CPB 
times were 32.4 and 53.4 minutes, respectively, in 
isolated AVR through a full sternotomy [12]. The ACC 
and CPB times in our study were longer because 3 
patients had previously undergone coronary artery 
bypass surgery or mitral valve replacement and in 1 
patient, AVR was performed with concomitant coro-
nary artery bypass grafting. Yu et al. [18] previously 
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published a study analyzing the early outcomes of 
conventional AVR compared with TAVI in severe AS 
patients. The duration of CPB and ACC in patients 
aged 75 years or more in the AVR group was 
126±34 minutes and 98±29 minutes, respectively; 
these results were inferior to those obtained with 
SU-AVR, although the study lacked statistical power.
During the follow-up period, the incidence of para-
valvular leakage and valve-related complications in 
terms of valve thrombosis, reoperation, and endo-
carditis was low (0%). These findings are in accord-
ance with the results of Santarpino et al. [3]. They 
reported that the paravalvular regurgitation rate was 
higher in the TAVI group than in the SU-AVR group 
(13.5% versus 0%, p=0.027) [3]. The PARTNER trial 
also demonstrated that TAVI resulted in much more 
frequent paravalvular leakage [11,19]. The primary 
reason for this may be related to the technique of 
decalcifying the native aortic valve. To avoid para-
valvular leakage as much as possible, calcium at the 
annulus, including severely fibrotic tissue, should be 
removed completely.
Although we did not observe moderate to severe 
paravalvular leakage or valvular regurgitation in our 
patients, there were 3 deaths among our 12 cases. 
Two cases were very high-risk patients preoperatively. 
One patient was an 81-year-old physician who had 
served in a sanatorium and was in cardiogenic shock 
with severe left ventricular failure at admission. On 
the third postoperative day, fungal pneumonia devel-
oped, but was well-treated at discharge. The other 
was a 62-year-old physician with severe esophageal 
varices associated with liver cirrhosis. Thus, our mor-
tality rate may have reflected the risk factor profile 
in terms of comorbidities and elderly patients.
The sutureless valve demonstrated excellent hemo-
dynamic performance, with a significant reduction of 
the pressure gradient (p＜0.001) and regression in 
left ventricular mass (p=0.006) in our echocardio-
graphic data. Flameng et al. [9] reported similar re-
sults, finding that the hemodynamics at the final fol-
low-up indicated good function, with low trans-
valvular pressure gradients (mean, 12 mm Hg and 
peak, 23 mm Hg). These stable hemodynamic results 
may support the efficacy and safety of the sutureless 
valve in high-risk populations.
The most important benefit of the sutureless valve 
is thought to be its long-term durability after 
implantation. According to the animal study con-
ducted by Kiefer et al. [20], the structural changes in 
the leaflets that were caused by crimping may have 
clinical significance regarding long-term durability. A 
sutureless valve does not require crimping for im-
plantation; instead, it only requires folding for it to 
be introduced, in contrast to the crimping required 
for TAVI. Therefore, in some patients with inter-
mediate or high surgical risk, for whom long-term 
survival is expected, SU-AVR may be a good alter-
native to TAVI or conventional AVR.
The major limitations of this study include its ret-
rospective nature, lack of a control group, and the 
inclusion of a small number of patients with short- 
term follow-up. Since the sample size was small, it is 
possible that certain factors associated with post-
operative complications or overall survival could 
have been overlooked due to a lack of statistical 
power. Because SU-AVR was first performed in Korea 
in December 2014, the mid- and long-term outcomes 
of SU-AVR in Korea are not yet available. A larger 
study of randomized patients with a longer follow-up 
duration is required for a more accurate comparison 
of the treatment modalities for severe AS in elderly 
patients and in those with comorbidities.
In conclusion, although SU-AVR did not show an 
advantage over TAVI or conventional AVR in terms 
of overall survival, the early clinical and hemody-
namic results appeared to be excellent in high-risk 
patients with comorbidities. Therefore, it seems that 
SU-AVR may be an alternative to TAVI in some pa-
tients with a high surgical risk profile for whom 
long-term survival is expected.
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